Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Positive data in Saxenda diabetes prevention study

Drug found to improve blood glucose and blood pressure levels

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

Sanofi reception

Sanofi’s Lantus follow-up nears European approval

CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

Sanofi reception

Sanofi gets green light for Lantus follow-up Toujeo

Once-daily basal insulin gains FDA approval for diabetes

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

- PMLiVE

Novo Nordisk’s oral GLP-1 analogue looks set for phase III

Semaglutide said to be one of the firm’s most promising prospects

Sanofi reception

Leaderless Sanofi sees strong growth

French firm confirms it will seek a new CEO this quarter

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links